Innohep

(Tinzaparin)

ApprovedSmall molecule

Tinzaparin is used to prevent and treat blood clots, particularly in patients undergoing surgery or those with certain types of blood clots in the legs or lungs.[2] Innohep is currently approved and in use across 15 indications[4].[1]

Innohep is one of 374 small molecule programs targeting Venous Thromboembolism. It is currently in Approved.

Indications

Total Trials

Active Trials

373

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Venous ThromboembolismActive, not recruiting

Colon AdenocarcinomaApproved

ThrombocytopeniaActive, not recruiting

Venous ThrombosisActive, not recruiting

PneumoniaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Deep Vein ThrombosisApproved

Malignant Epithelial Tumor of OvaryApproved

Pulmonary EmbolismActive, not recruiting

PreeclampsiaActive, not recruiting

Venous ThromboembolismPreclinical

Active, not recruiting

Colon AdenocarcinomaApproved

Approved

ThrombocytopeniaApproved

Active, not recruiting

Venous ThrombosisPhase 3

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Deep Vein ThrombosisApproved

Approved

Malignant Epithelial Tumor of OvaryApproved

Approved

Pulmonary EmbolismApproved

Active, not recruiting

PreeclampsiaApproved

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Innohep

Alnylam Pharmaceuticals

Approved

2 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 4

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 5

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 8

SARS-COV-2 VACCINE

Moderna

Preclinical

2 9

Nadroparin

GSK

Preclinical

1 10

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Ovarian Cancer

NCT05284552

Q1 2027

Post-ApprovalRecruiting

Thrombocytopenia

NCT05255003

Q3 2027

Post-ApprovalRecruiting

Preeclampsia

NCT07361679

Q3 2028

Phase 3Recruiting

Thrombosis

NCT06370273

Clinical

Trials by Indication[1]

Venous Thromboembolism3 trials

A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

Unknown status·TThe University of Hong Kong·Phase 3·NCT03240120·99 enrolled

Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)

Completed· LEO Pharma logo

LEO Pharma··NCT03099031·420 enrolled

Venous Thromboembolism Prophylaxis Post Cesarean Section

Unknown status·KKing Saud University··NCT01321788·300 enrolled

Pregnancy2 trials

Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing

Completed·UUniversity of Calgary·Phase 4·NCT00851864·13 enrolled

Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?

Completed·UUniversity of Aarhus·Phase 4·NCT01390051·50 enrolled

Venous thrombosis2 trials

Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis

Completed·HHospital Universitari de Bellvitge·Phase 4·NCT00689520·241 enrolled

Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities

Completed·—·Phase 3·NCT00628576·99 enrolled

COVID-192 trials

Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients

Unknown status·UUniversity Hospital of Patras··NCT05036824·300 enrolled

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial

Active, not recruiting·UUniversity of Melbourne·Phase 3·NCT04483960·2,200 enrolled

Cesarean Section1 trial

The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section

Completed·OOttawa Hospital Research Institute·Phase 2/3·NCT00225108·30 enrolled

16 more indications

Low Molecular Weight Heparin1 trial

MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis

Terminated·—·N/A·NCT00135863·36 enrolled

Colon Cancer1 trial

Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer

Completed·OOttawa Hospital Research Institute·N/A·NCT00967148·18 enrolled

Anticoagulant1 trial

Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer

Completed·—·Phase 2·NCT02260414·19 enrolled

MPA1 trial

Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses

Completed·MMaisonneuve-Rosemont Hospital··NCT02719418·28 enrolled

Pneumonia1 trial

Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)

Completed·—·N/A·NCT04730856·311 enrolled

Post-thrombotic Syndrome1 trial

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

Terminated·SSunnybrook Health Sciences Centre·Phase 4·NCT04794569·9 enrolled

Colorectal Cancer1 trial

Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer

Completed·OOttawa Hospital Research Institute·Phase 3·NCT01455831·616 enrolled

Kidney Failure1 trial

Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

Terminated·SSt. Joseph's Healthcare Hamilton·N/A·NCT00186745·148 enrolled

Preeclampsia1 trial

LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention

Recruiting·—·Phase 4·NCT07361679·100 enrolled

Metastatic Colorectal Cancer1 trial

TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

Completed·GGalician Research Group on Digestive Tumors·Phase 3·NCT05625932·232 enrolled

Deep Vein Thrombosis1 trial

Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis

Active, not recruiting·—·N/A·NCT04741464·9 enrolled

Anticoagulation1 trial

Use of Tinzaparin for Anticoagulation in Hemodialysis

Completed·CChristine Ribic·Phase 4·NCT01930396·191 enrolled

Pulmonary Embolism1 trial

Tinzaparin in the Treatment of the Acute Pulmonary Embolism

Completed·—·Phase 4·NCT00711308·102 enrolled

Thrombocytopenia1 trial

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

Recruiting·TTzu-Fei Wang·Phase 4·NCT05255003·50 enrolled

Ovarian Cancer1 trial

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

Recruiting·UUniversity Hospital, Linkoeping·Phase 2·NCT05284552·40 enrolled

Thrombosis1 trial

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.

Recruiting·QQueen Mary University of London·Phase 3·NCT06370273·10,044 enrolled

Regulatory

FDA Approval Timeline[5]

Jul 14, 2000

INNOHEP

NDA NDA020484

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for Tinzaparin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Innohep drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Tinzaparin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Tinzaparin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020484). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Alnylam Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Alnylam Pharmaceuticals

Innohep

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q3 2028

Trials by Indication[1]

Venous Thromboembolism3 trials

Pregnancy2 trials

Venous thrombosis2 trials

COVID-192 trials

Cesarean Section1 trial

Low Molecular Weight Heparin1 trial

Colon Cancer1 trial

Anticoagulant1 trial

MPA1 trial

Pneumonia1 trial

Post-thrombotic Syndrome1 trial

Colorectal Cancer1 trial

Kidney Failure1 trial

Preeclampsia1 trial

Metastatic Colorectal Cancer1 trial

Deep Vein Thrombosis1 trial

Anticoagulation1 trial

Pulmonary Embolism1 trial

Thrombocytopenia1 trial

Ovarian Cancer1 trial

Thrombosis1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News